Phase II Randomized Trial With A Modified Dose & Schedule of Subcutaneously Administered Azacitidine & Erythropoietin v Azacitidine Alone in Patients With Low-Risk Myelodysplastic Syndromes (Less Than 11% Marrow Peripheral Blood Blasts).

Trial Profile

Phase II Randomized Trial With A Modified Dose & Schedule of Subcutaneously Administered Azacitidine & Erythropoietin v Azacitidine Alone in Patients With Low-Risk Myelodysplastic Syndromes (Less Than 11% Marrow Peripheral Blood Blasts).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Azacitidine (Primary) ; Erythropoietins
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jan 2009 Planned end date changed from 1 Sep 2008 to 1 Dec 2008 as reported by ClinicalTrials.gov.
    • 22 Jan 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 22 Jan 2009 Planned number of patients amended from 48 to 15 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top